The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The closing price of Viracta Therapeutics Inc (NASDAQ: VIRX) was $0.15 for the day, down -4.37% from the previous closing price of $0.16. In other words, the price has decreased by -$4.37 from its previous closing price. On the day, 1.15 million shares were traded. VIRX stock price reached its highest trading level at $0.1579 during the session, while it also had its lowest trading level at $0.1315.
Ratios:
Our analysis of VIRX’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 0.76 and its Current Ratio is at 0.76.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Leerink Partners on August 16, 2024, Downgraded its rating to Market Perform and sets its target price to $3 from $5 previously.
On February 01, 2022, RBC Capital Mkts started tracking the stock assigning a Outperform rating and target price of $10.
On May 03, 2021, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $35.H.C. Wainwright initiated its Buy rating on May 03, 2021, with a $35 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Feb 27 ’24 when Chevallard Daniel R. sold 3,405 shares for $0.73 per share. The transaction valued at 2,493 led to the insider holds 102,306 shares of the business.
Rothera Mark bought 52,094 shares of VIRX for $25,734 on Nov 30 ’23. The President and CEO now owns 52,094 shares after completing the transaction at $0.49 per share. On Dec 01 ’23, another insider, Rothera Mark, who serves as the President and CEO of the company, bought 47,906 shares for $0.49 each. As a result, the insider paid 23,627 and bolstered with 100,000 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VIRX now has a Market Capitalization of 5951997 and an Enterprise Value of 489971.
Stock Price History:
Over the past 52 weeks, VIRX has reached a high of $1.31, while it has fallen to a 52-week low of $0.15. The 50-Day Moving Average of the stock is -30.88%, while the 200-Day Moving Average is calculated to be -73.21%.
Shares Statistics:
VIRX traded an average of 1.06M shares per day over the past three months and 2080420 shares per day over the past ten days. A total of 39.09M shares are outstanding, with a floating share count of 27.94M. Insiders hold about 29.69% of the company’s shares, while institutions hold 13.08% stake in the company. Shares short for VIRX as of 1730332800 were 2691476 with a Short Ratio of 2.54, compared to 1727654400 on 1326060. Therefore, it implies a Short% of Shares Outstanding of 2691476 and a Short% of Float of 8.68.
